China mulls price controls for imported drugs
This article was originally published in Scrip
There have been more than 20 rounds of price reductions for domestically manufactured medicines in China over the past decade, during which time imported and innovative drugs have enjoyed something of a favoured status.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.